Roche

Roche obesity drug drives 15.5% weight loss in diabetes trial

Roche announced on Tuesday that its experimental obesity drug enicepatide helped patients with type 2 diabetes achieve an average 15.5% body weight reduction and restored many to non-diabetic blood sugar levels in a mid-stage clinical trial, bolstering the Swiss drugmaker's…

Immunotherapy nearly doubles survival time in early-stage lung cancer trial

Adding the immunotherapy drug atezolizumab to chemotherapy before and after surgery nearly doubled the time patients with early-stage lung cancer lived without their disease returning, according to final results from the Phase 3 IMpower030 trial presented on September 12 at…

FDA clears Roche, Eli Lilly blood test for Alzheimer’s

The U.S. Food and Drug Administration has cleared a blood test developed by Roche in collaboration with Eli Lilly that can help detect signs of Alzheimer's disease through a simple blood draw, potentially transforming how the condition is diagnosed across…

Roche, Recursion advance first AI-discovered drug target

Roche and its subsidiary Genentech have advanced the first neuroscience drug target to emerge from their artificial intelligence partnership with Recursion Pharmaceuticals, moving it into an early discovery program in what both companies describe as a proof point for AI-driven…

Roche unveils trial to prevent Alzheimer’s before symptoms appear

Roche has revealed the design of PrevenTRON, a Phase III trial that will test whether its experimental drug trontinemab can prevent Alzheimer's disease in people who show no cognitive symptoms but carry biological markers of the illness. The study design…